M8 Pharmaceuticals Signs An Exclusive Licensing Agreement With Supernus Pharmaceuticals To Seek Regulatory Approval And Commercialize Qelbree Under M8's Trademark In Latin America
Portfolio Pulse from Benzinga Newsdesk
M8 Pharmaceuticals has entered into an exclusive licensing agreement with Supernus Pharmaceuticals (NASDAQ:SUPN) to seek regulatory approval and commercialize Qelbree, a non-stimulant ADHD medication, in Latin America. Qelbree is approved in the US for treating ADHD in adults and children aged 6 and older. This partnership aligns with Acino's mission to expand access to innovative medicines in Latin America and strengthens its position in the CNS therapeutic area. Supernus has chosen M8 as a partner for Qelbree's regulatory approval and commercialization in Mexico and Brazil, highlighting the company's commitment to addressing ADHD treatment challenges globally.
May 07, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Supernus Pharmaceuticals partners with M8 Pharmaceuticals to commercialize Qelbree in Latin America, aiming to expand its global footprint and address ADHD treatment needs.
The partnership with M8 Pharmaceuticals to commercialize Qelbree in Latin America could potentially open new markets for Supernus Pharmaceuticals, increasing its revenue streams and enhancing its global presence in the CNS therapeutic area. Given the strategic nature of this partnership and the focus on a non-stimulant ADHD treatment, which is a significant addition to the treatment options available, this move is likely to be viewed positively by investors and could lead to a short-term positive impact on SUPN's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90